Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Milan Istituto Oncologico Veneto IRCCS, Padova, PD Ospedale Santa Chiara, Pisa, PI